United Therapeutics Corporation
UTHR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $18,361 | $12,959 | $13,841 | $15,948 |
| - Cash | $1,340 | $1,593 | $1,900 | $1,697 |
| + Debt | $0 | $0 | $200 | $300 |
| Enterprise Value | $17,021 | $11,366 | $12,141 | $14,551 |
| Revenue | $800 | $799 | $794 | $736 |
| % Growth | 0.1% | 0.5% | 7.9% | – |
| Gross Profit | $699 | $711 | $702 | $660 |
| % Margin | 87.4% | 89% | 88.4% | 89.7% |
| EBITDA | $463 | $437 | $383 | $424 |
| % Margin | 57.9% | 54.7% | 48.2% | 57.6% |
| Net Income | $339 | $310 | $322 | $301 |
| % Margin | 42.4% | 38.8% | 40.6% | 40.9% |
| EPS Diluted | 7.16 | 6.41 | 6.63 | 6.19 |
| % Growth | 11.7% | -3.3% | 7.1% | – |
| Operating Cash Flow | $562 | $192 | $461 | $341 |
| Capital Expenditures | -$211 | -$62 | -$75 | -$87 |
| Free Cash Flow | $352 | $130 | $386 | $255 |